BDSIのチャート
BDSIの企業情報
symbol | BDSI |
---|---|
会社名 | BioDelivery Sciences International Inc (バイオデリバリ―・サイエンシズ・インタ―ナショナル) |
分野(sector) | Health Care ヘルスケア |
産業(industry) | Major Pharmaceuticals |
業種 | 医薬品 医療関連(Health Care) |
概要 | 事業概要 バイオデリバリ・サイエンシズ・インターナショナル(BioDelivery Sciences International Inc.)は専門製薬会社であり、自社独力或いは第三者との提携で、医療ニーズに応じた治療薬の開発・商業化に従事する。同社は主に疼痛管理とがん補助療法分野向けの医薬品を開発していた。またはそれを開発している。同社は頬粘膜に作用する小・侵食性高分子フィルムである生体侵食性粘膜接着性システム(BEMA)技術を利用して薬品と薬品候補の製剤を行う。同社の米国食品医薬品局(FDA)認可の製品「ONSOLIS」及びその薬品候補のパイプラインはBEMA技術を利用している。 バイオデリバリ―・サイエンシズ・インタ―ナショナルは米国のバイオ医薬品メ―カ―。独自に又は他の医薬品メ―カ―と共同で、実績のある治療薬の新しいアプリケ―ションを開発、製品化。疼痛管理と依存の分野を主とした医薬品を開発。製品を開発する際に、独自開発で特許取得済みの生体内分解性粘膜付着性(BEMA)ドラッグデリバリ―技術を応用する。 BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation. |
本社所在地 | 4131 ParkLake Avenue Suite 225 Raleigh NC 27612 USA |
代表者氏名 | Frank E. O'Donnell フランク・E・オドネル |
代表者役職名 | Executive Chairman of the Board 取締役会長 |
電話番号 | +1 919-582-9050 |
設立年月日 | 35431 |
市場名 | NASDAQ Small Cap |
ipoyear | ―年 |
従業員数 | 116人 |
url | www.bdsi.com |
nasdaq_url | https://www.nasdaq.com/symbol/bdsi |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -33.52800 |
終値(lastsale) | 3.26 |
時価総額(marketcap) | 194162910.5 |
時価総額 | 時価総額(百万ドル) 202.50120 |
売上高 | 売上高(百万ドル) 47.22100 |
企業価値(EV) | 企業価値(EV)(百万ドル) 196.17320 |
当期純利益 | 当期純利益(百万ドル) -48.64000 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 BioDelivery Sciences International Inc. revenues decreased 39% to $23.5M. Net loss totaled $20.5M vs. income of $33.4M. Revenues reflect Contract revenues decrease of 95% to $1M Product royalty revenues decrease of 20% to $1.8M Research and development reimbursements decrease from $267K to $0K. Net loss reflects Bargain purchase gain decrease from $27.3M (income) to $0K. |
BDSIのテクニカル分析
BDSIのニュース
SA readers grab Inspirato, HOOKIPA and megacaps; merger deal pushes them away from BDSI 2022/02/27 19:34:56 Seeking Alpha
SA readers graivated to extremes last week, looking at both smaller newsmakers and megacap safe havens. They added ISPO, HOOK, GOOGL and AAPL. Also, they dropped BDSI after a merger deal.
Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results 2022/02/24 21:01:00 GlobeNewswire
– BDSI Acquisition Expected to Close Late Q1 2022 –
BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine 2022/02/24 13:30:00 GlobeNewswire
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults
SHAREHOLDER ALERT: WeissLaw LLP Reminds BDSI, FTSI, CCMP, and FLOW Shareholders About Its Ongoing Investigations 2022/02/22 01:14:00 Kwhen Finance
SA readers grab Inspirato, HOOKIPA and megacaps; merger deal pushes them away from BDSI 2022/02/27 19:34:56 Seeking Alpha
SA readers graivated to extremes last week, looking at both smaller newsmakers and megacap safe havens. They added ISPO, HOOK, GOOGL and AAPL. Also, they dropped BDSI after a merger deal.
Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results 2022/02/24 21:01:00 GlobeNewswire
– BDSI Acquisition Expected to Close Late Q1 2022 –
BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine 2022/02/24 13:30:00 GlobeNewswire
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults
SHAREHOLDER ALERT: WeissLaw LLP Reminds BDSI, FTSI, CCMP, and FLOW Shareholders About Its Ongoing Investigations 2022/02/22 01:14:00 Kwhen Finance
SA readers grab Inspirato, HOOKIPA and megacaps; merger deal pushes them away from BDSI 2022/02/27 19:34:56 Seeking Alpha
SA readers graivated to extremes last week, looking at both smaller newsmakers and megacap safe havens. They added ISPO, HOOK, GOOGL and AAPL. Also, they dropped BDSI after a merger deal.
Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results 2022/02/24 21:01:00 GlobeNewswire
– BDSI Acquisition Expected to Close Late Q1 2022 –